Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
KTTA vs ISPC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
KTTA Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–1 Matrix Metrics)
KTTA Overall Winner
6-Pillar Tally: KTTA 2 – 2 ISPC (2 Tie)
Matrix Metrics: KTTA 6 – 1 ISPC
As of Nov 20, 2026, Pasithea Therapeutics Corp. (KTTA) is the stronger overall head-to-head candidate over iSpecimen Inc. (ISPC) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). KTTA carries a Unified Composite Score of 42.1/100 (HOLD) at $0.48 (N/M Forward P/E, 0.0% operating margin), whereas ISPC carries 41.6/100 (SELL) at $0.46 (N/M Forward P/E, -1455.3% operating margin).
- Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile ISPC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About KTTA vs ISPC
KTTA
Head-to-Head Winner
Pasithea Therapeutics Corp. Common Stock
$0.48
-0.48% 1D
Market Cap
$17.7M
TTM Revenue
$486,559
Forward P/E
N/M
Beta / 30D Vol
0.68β · 185% Vol
Unified Composite Score
42.1
HOLD
Tech 20.0
Fund 40.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
ISPC
iSpecimen Inc. Common Stock
$0.46
-13.58% 1D
Market Cap
$3.1M
TTM Revenue
$603,744
Forward P/E
N/M
Beta / 30D Vol
-10.07β · 74% Vol
Unified Composite Score
41.6
SELL
Tech 25.0
Fund 43.0
Flow 50.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (KTTA 2 – 2 ISPC)
1. Valuation Multiples
ISPC
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
36.3x
0.8x
2. Growth & Scale
KTTA
Revenue Growth (YoY)
+1498.1%
+128.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$486,559
$603,744
Market Cap
$17.7M
$3.1M
3. Profitability & Quality
KTTA
Gross Margin
-0.5%
-42.1%
Operating Margin
0.0%
-1455.3%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-88.8%
-303.9%
4. Balance Sheet & Cash Flow
ISPC
Cash Generation (TTM)
-$18M
-$8.7M EBITDA
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$1.31 Book/Sh · -88.8% ROE
$2.6M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Distribution
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: KTTA (6) vs ISPC (1)| Institutional Metric | KTTA | ISPC | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $17.7M | $3.1M | KTTA | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +1498.1% | +128.9% | KTTA | |
| Operating Margin (TTM) | 0.0% | -1455.3% | KTTA | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -88.8% | -303.9% | KTTA | |
| 52-Week Range Position | 11% ($0–$2) | 5% ($0–$7) | KTTA | |
| Beta / 30D Volatility | 0.68β · 185% Vol | -10.07β · 74% Vol | ISPC | |
| Unified Institutional Score | 42.1 / 100 (HOLD) | 41.6 / 100 (SELL) | KTTA | |
| Trailing 12M Revenue (USD) | $486,559 | $603,744 | Scale | |
| Gross Profit Margin (TTM) | -0.5% | -42.1% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 36.3x EV/Rev | N/M PEG · 0.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$18M ($1.31 Book/Sh · -88.8% ROE) | -$8.7M EBITDA ($2.6M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
KTTA +52.72 pp
3M Horizon
KTTA +65.73 pp
6M Horizon
KTTA +55.18 pp
1Y Horizon
KTTA +10.59 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | KTTA Revenue | ISPC Revenue | KTTA Op. Margin | ISPC Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | N/A | $10M | N/A | -29.4% | ISPC |
| FY2021 | $0M | $10M | -29925.7% | -53.2% | ISPC |
| FY2022 | $0M | $10M | -2587.3% | -97.9% | ISPC |
| FY2023 | N/A | $10M | N/A | -112.5% | ISPC |
| FY2024 | N/A | $10M | N/A | -137.0% | ISPC |
| FY2025 | N/A | $0M | N/A | -465.4% | ISPC |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
KTTA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact KTTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ISPC
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ISPC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
KTTA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ISPC Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ KTTA vs ISPC Key Questions & Quantitative Answers
As of Nov 20, 2026, Pasithea Therapeutics Corp. (KTTA) is the stronger overall head-to-head candidate over iSpecimen Inc. (ISPC) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). KTTA carries a Unified Composite Score of 42.1/100 (HOLD) at $0.48 (N/M Forward P/E, 0.0% operating margin), whereas ISPC carries 41.6/100 (SELL) at $0.46 (N/M Forward P/E, -1455.3% operating margin). Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile ISPC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KTTA leads the Growth & Scale pillar: KTTA posts +1498.1% YoY revenue growth and +0.0% YoY earnings growth on $486,559 TTM revenue (-0.5% gross margin, 0.0% operating margin), compared with ISPC at +128.9% YoY revenue growth and +0.0% YoY earnings growth on $603,744 TTM revenue (-42.1% gross margin, -1455.3% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), KTTA cumulative revenue shifted N/A while ISPC shifted +0.0%. In operating R&D and SG&A reinvestment, KTTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ISPC.
ISPC screens cheaper on headline valuation multiples. KTTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 36.3x EV/Revenue (unreported FCF margin), whereas ISPC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KTTA (-88.8% ROE) versus ISPC (-303.9% ROE) capital efficiency.
In options market volatility and institutional positioning, KTTA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 185% Vol realized risk). By comparison, ISPC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-10.07β · 74% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ISPC vs KTTA · Reverse Pair
KTTA vs QNRX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal